IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.993
AS - Asia 4.891
NA - Nord America 4.437
SA - Sud America 1.088
AF - Africa 87
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 15.508
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.263
RU - Federazione Russa 2.803
CN - Cina 1.711
SG - Singapore 1.636
BR - Brasile 899
SE - Svezia 731
HK - Hong Kong 582
VN - Vietnam 444
IT - Italia 344
RO - Romania 269
FR - Francia 238
DE - Germania 203
BD - Bangladesh 115
GB - Regno Unito 112
IN - India 98
CA - Canada 86
AR - Argentina 75
FI - Finlandia 74
MX - Messico 51
ID - Indonesia 45
TR - Turchia 41
ZA - Sudafrica 39
PL - Polonia 37
IQ - Iraq 34
EC - Ecuador 33
NL - Olanda 33
AT - Austria 30
CO - Colombia 30
ES - Italia 28
JP - Giappone 26
IE - Irlanda 21
PK - Pakistan 21
UA - Ucraina 17
AE - Emirati Arabi Uniti 15
LT - Lituania 15
MY - Malesia 15
PH - Filippine 15
UZ - Uzbekistan 15
VE - Venezuela 15
MA - Marocco 13
CL - Cile 12
SA - Arabia Saudita 12
TN - Tunisia 11
NP - Nepal 10
BO - Bolivia 7
DZ - Algeria 7
LU - Lussemburgo 7
MD - Moldavia 7
PY - Paraguay 7
CZ - Repubblica Ceca 6
JM - Giamaica 6
TH - Thailandia 6
BE - Belgio 5
EG - Egitto 5
EU - Europa 5
GT - Guatemala 5
IL - Israele 5
IR - Iran 5
KW - Kuwait 5
NI - Nicaragua 5
OM - Oman 5
PA - Panama 5
PE - Perù 5
AU - Australia 4
KE - Kenya 4
UY - Uruguay 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JO - Giordania 3
KG - Kirghizistan 3
KR - Corea 3
KZ - Kazakistan 3
QA - Qatar 3
AL - Albania 2
BB - Barbados 2
BG - Bulgaria 2
BS - Bahamas 2
GE - Georgia 2
LB - Libano 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GF - Guiana Francese 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
LR - Liberia 1
LV - Lettonia 1
Totale 15.500
Salva come PNG Salva come JPEG
Città #
Dallas 1.431
Singapore 672
Moscow 643
Hong Kong 572
San Jose 491
Ashburn 468
Shanghai 283
Hefei 232
Lawrence 219
Princeton 219
Lauterbourg 201
Beijing 191
New York 173
Ho Chi Minh City 161
Milan 120
São Paulo 97
Hanoi 96
Los Angeles 93
Nuremberg 57
Helsinki 53
Santa Clara 47
Boardman 44
Munich 41
Orem 40
Warsaw 35
Guangzhou 34
Rome 33
Chennai 29
Denver 28
Montreal 28
Tokyo 25
Mexico City 24
Pune 24
Washington 24
Atlanta 23
Johannesburg 23
Seattle 23
Brooklyn 21
Council Bluffs 21
Curitiba 21
Frankfurt am Main 21
Manchester 21
Da Nang 19
Rio de Janeiro 19
London 18
Belo Horizonte 17
Chicago 17
Poplar 17
Ankara 16
Dublin 16
Haiphong 16
Shenzhen 16
Buffalo 15
Houston 15
Stockholm 15
Tashkent 15
Toronto 15
Turku 15
Amsterdam 14
Boston 14
Phoenix 14
Vienna 14
Brasília 13
Campinas 13
Hangzhou 13
Hải Dương 12
The Dalles 12
Baghdad 11
Goiânia 11
Guayaquil 11
Porto Alegre 11
Quito 11
Tianjin 11
Miami 10
Reston 10
Kuala Lumpur 9
Querétaro 9
Barnet 8
Bogotá 8
Buenos Aires 8
Cesano Boscone 8
Istanbul 8
Las Vegas 8
New Delhi 8
Salvador 8
Betim 7
Charlotte 7
Ha Long 7
Kassel 7
Mumbai 7
Philadelphia 7
Quanzhou 7
San Francisco 7
Sorocaba 7
São José do Rio Preto 7
Xi'an 7
Cape Town 6
Changsha 6
City of London 6
Columbus 6
Totale 7.751
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.363
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 209
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 181
Biobanking for COVID-19 research 148
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 146
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 146
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 145
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 125
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 116
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 115
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 114
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 113
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 113
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 112
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 111
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 108
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 107
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 103
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients with Advanced Liver Disease during Anti-HCV Treatment with Direct-Acting Antiviral Regimens Including Ribavirin 101
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 100
Bictegravir 100
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 99
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 99
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 98
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 97
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 95
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 95
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 94
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 94
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 93
ABC of AIDS: Treatment of infections and antiviral agents 92
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 91
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 91
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 89
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 88
Experiences with immunomodulant agents in HIV infections 85
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 85
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 84
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 83
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 83
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 82
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 82
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 82
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 82
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial 79
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 78
Analysis of impediments to the maintenance in care of people with HIV in Italy 77
Immunological status in heroin addicts: effects of methadone maintenance treatment 76
Darunavir for the treatment of HIV infection 76
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population 76
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 76
Hepatitis delta infection among persons living with HIV in Europe 76
Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study 74
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 73
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV 72
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 72
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 72
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe 72
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 71
Early diagnosis of HIV infection in infants 70
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman 68
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 68
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 68
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 68
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 67
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 67
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 67
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 67
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 67
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 67
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 67
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 67
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 67
Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study 66
Impact of HAART on liver histology of HIV/HCV coinfected patients 65
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 65
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 65
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 65
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 65
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 65
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 64
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts 64
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 63
Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: An Italian pilot study in a dental clinic 63
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 62
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 62
Polymorphonuclear leucocytes functions from premature infants after prevention of respiratory distress syndrome with betamethasone and ambroxol 61
Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women 61
Immune recovery and T cell subset analysis during effective treatment with maraviroc 61
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy 61
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 61
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 61
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 61
No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study 60
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients 60
Risk behaviour and HTLV-1 seropositivity in injecting drug users 60
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort 59
Milan as possible starting point of LAV/HTLV III epidemic among Italian drug addicts 59
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection 59
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA 59
Totale 9.681
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.134
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.134
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/20253.101 375 58 37 81 83 256 711 232 487 360 162 259
2025/202610.349 718 880 1.425 1.260 633 308 927 646 2.491 559 245 257
2026/202780 80 0 0 0 0 0 0 0 0 0 0 0
Totale 15.778